Standard of Care Treatment
KYSA-6
Phase 3 small_molecule active
Quick answer
Standard of Care Treatment for Myasthenia Gravis is a Phase 3 program (small_molecule) at Kyverna Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kyverna Therapeutics
- Indication
- Myasthenia Gravis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active